PharmaCyte Biotech Inc banner

PharmaCyte Biotech Inc
NASDAQ:PMCB

Watchlist Manager
PharmaCyte Biotech Inc Logo
PharmaCyte Biotech Inc
NASDAQ:PMCB
Watchlist
Price: 0.5402 USD -0.06%
Market Cap: $5.8m

Wall St Price Targets

PMCB Price Targets Summary
PharmaCyte Biotech Inc

There are no price targets for PMCB.
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
PharmaCyte Biotech Inc Competitors:
Price Targets
NEPHROPLUS
Nephrocare Health Services Ltd
24% Upside
3363
FOCI Fiber Optic Communications Inc
-1% Downside
AYTU
Aytu Biopharma Inc
329% Upside
ARDX
Ardelyx Inc
251% Upside

Revenue
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is PMCB's stock price target?
Not Available

PMCB does not have any price targets made by Wall Street professionals.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett